» Articles » PMID: 15959923

Metabolic Differences Between Primary and Recurrent Human Brain Tumors: a 1H NMR Spectroscopic Investigation

Overview
Journal NMR Biomed
Publisher Wiley
Date 2005 Jun 17
PMID 15959923
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

High-resolution proton magnetic resonance spectroscopy was performed on tissue specimens from 33 patients with astrocytic tumors (22 astrocytomas, 11 glioblastomas) and 13 patients with meningiomas. For all patients, samples of primary tumors and their first recurrences were examined. Increased anaplasia, with respect to malignant transformation, resulting in a higher malignancy grade, was present in 11 recurrences of 22 astrocytoma patients. Spectroscopic features of tumor types, as determined on samples of the primary occurrences, were in good agreement with previous studies. Compared with the respective primary astrocytomas, characteristic features of glioblastomas were significantly increased concentrations of alanine (Ala) (p = 0.005), increased metabolite ratios of glycine (Gly)/total creatine (tCr) (p = 0.0001) and glutamate (Glu)/glutamine (Gln) (p = 0.004). Meningiomas showed increased Ala (p = 0.02) and metabolite ratios [Gly, total choline (tCho), Ala] over tCr (p = 0.001) relative to astrocytomas, and N-acetylaspartate and myo-inositol were absent. Metabolic changes of an evolving tumor were observed in recurrent astrocytomas: owing to their consecutive assessments, more indicators of malignant degeneration were detected in astrocytoma recurrences (e.g. Gly, p = 0.029; tCho, p = 0.034; Glu, p = 0.015; tCho/tCr, p = 0.001) in contrast to the comparison of primary astrocytomas with primary glioblastomas. The present investigation demonstrated a correlation of the tCho-signal with tumor progression. Significantly elevated concentrations of Ala (p = 0.037) and Glu (p = 0.003) and metabolite ratio tCho/tCr (p = 0.005) were even found in recurrent low-grade astrocytomas with unchanged histopathological grading (n = 11). This may be related to an early stage of malignant transformation, not yet detectable morphologically, and emphasizes the high sensitivity of 1H NMR spectroscopy in elucidating characteristics of brain tumor metabolism.

Citing Articles

Research of Pesticide Metabolites in Human Brain Tumor Tissues by Chemometrics-Based Gas Chromatography-Mass Spectrometry Analysis for a Hypothetical Correlation between Pesticide Exposure and Risk Factor of Central Nervous System Tumors.

Louati K, Kolsi F, Kallel R, Gdoura Y, Borni M, Hakim L ACS Omega. 2023; 8(32):29812-29835.

PMID: 37599976 PMC: 10433342. DOI: 10.1021/acsomega.3c04592.


Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas.

Ijare O, Hambarde S, Brasil da Costa F, Lopez S, Sharpe M, Helekar S Neuro Oncol. 2021; 24(4):556-568.

PMID: 34515312 PMC: 8972231. DOI: 10.1093/neuonc/noab219.


The Role of Preclinical Models in Creatine Transporter Deficiency: Neurobiological Mechanisms, Biomarkers and Therapeutic Development.

Ghirardini E, Calugi F, Sagona G, Di Vetta F, Palma M, Battini R Genes (Basel). 2021; 12(8).

PMID: 34440297 PMC: 8392480. DOI: 10.3390/genes12081123.


Utility of 3T single-voxel proton MR spectroscopy for differentiating intracranial meningiomas from intracranial enhanced mass lesions.

Matsusue E, Inoue C, Tabuchi S, Yoshioka H, Nagao Y, Matsumoto K Acta Radiol Open. 2021; 10(4):20584601211009472.

PMID: 34211737 PMC: 8215334. DOI: 10.1177/20584601211009472.


Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy.

Dastmalchi F, Deleyrolle L, Karachi A, Mitchell D, Rahman M Front Oncol. 2021; 11:691246.

PMID: 34150663 PMC: 8209463. DOI: 10.3389/fonc.2021.691246.